Literature DB >> 22178931

Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery.

Ana Carolina Santos de Souza1, Giselle Zenker Justo, Daniele Ribeiro de Araújo, Alexandre D Martins Cavagis.   

Abstract

Cancer cells are the product of genetic disorders that alter crucial intracellular signaling pathways associated with the regulation of cell survival, proliferation, differentiation and death mechanisms. The role of oncogene activation and tumor suppressor inhibition in the onset of cancer is well established. Traditional antitumor therapies target specific molecules, the action/expression of which is altered in cancer cells. However, since the physiology of normal cells involves the same signaling pathways that are disturbed in cancer cells, targeted therapies have to deal with side effects and multidrug resistance, the main causes of therapy failure. Since the pioneering work of Otto Warburg, over 80 years ago, the subversion of normal metabolism displayed by cancer cells has been highlighted by many studies. Recently, the study of tumor metabolism has received much attention because metabolic transformation is a crucial cancer hallmark and a direct consequence of disturbances in the activities of oncogenes and tumor suppressors. In this review we discuss tumor metabolism from the molecular perspective of oncogenes, tumor suppressors and protein signaling pathways relevant to metabolic transformation and tumorigenesis. We also identify the principal unanswered questions surrounding this issue and the attempts to relate these to their potential for future cancer treatment. As will be made clear, tumor metabolism is still only partly understood and the metabolic aspects of transformation constitute a major challenge for science. Nevertheless, cancer metabolism can be exploited to devise novel avenues for the rational treatment of this disease.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178931     DOI: 10.1159/000335792

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  9 in total

1.  TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells.

Authors:  F Lozupone; M Borghi; F Marzoli; T Azzarito; P Matarrese; E Iessi; G Venturi; S Meschini; A Canitano; R Bona; A Cara; S Fais
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

Review 2.  The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.

Authors:  Li Yu; Xun Chen; Liantang Wang; Shangwu Chen
Journal:  Oncotarget       Date:  2016-06-21

3.  Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling.

Authors:  Xiao-Yu Chen; De-Fang Li; Ji-Chun Han; Bo Wang; Zheng-Ping Dong; Li-Na Yu; Zhao-Hai Pan; Chuan-Jun Qu; Ying Chen; Shi-Guo Sun; Qiu-Sheng Zheng
Journal:  Oncotarget       Date:  2017-05-23

4.  Metabolic remodeling in human colorectal cancer and surrounding tissues: alterations in regulation of mitochondrial respiration and metabolic fluxes.

Authors:  Vladimir Chekulayev; Kati Mado; Igor Shevchuk; Andre Koit; Andrus Kaldma; Aleksandr Klepinin; Natalja Timohhina; Kersti Tepp; Manana Kandashvili; Lyudmila Ounpuu; Karoliina Heck; Laura Truu; Anu Planken; Vahur Valvere; Tuuli Kaambre
Journal:  Biochem Biophys Rep       Date:  2015-08-29

5.  TPI1-reduced extracellular vesicles mediated by Rab20 downregulation promotes aerobic glycolysis to drive hepatocarcinogenesis.

Authors:  Bonnie Hei Man Liu; Sze Keong Tey; Xiaowen Mao; Angel Po Yee Ma; Cherlie Lot Sum Yeung; Samuel Wan Ki Wong; Tung Him Ng; Yi Xu; Yue Yao; Eva Yi Man Fung; Kel Vin Tan; Pek-Lan Khong; Daniel Wai-Hung Ho; Irene Oi-Lin Ng; Alexander Hin Ning Tang; Shao Hang Cai; Jing Ping Yun; Judy Wai Ping Yam
Journal:  J Extracell Vesicles       Date:  2021-08-11

6.  Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients.

Authors:  Jiang Zhu; Yu-Nong Wu; Wei Zhang; Xiao-Min Zhang; Xu Ding; Huai-Qi Li; Meiyu Geng; Zuo-Quan Xie; He-Ming Wu
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 7.  Tumor glycolysis as a target for cancer therapy: progress and prospects.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Jean-Francois H Geschwind
Journal:  Mol Cancer       Date:  2013-12-03       Impact factor: 27.401

Review 8.  The Glycolytic Switch in Tumors: How Many Players Are Involved?

Authors:  Li Yu; Xun Chen; Xueqi Sun; Liantang Wang; Shangwu Chen
Journal:  J Cancer       Date:  2017-09-20       Impact factor: 4.207

Review 9.  Current Methods of Magnetic Resonance for Noninvasive Assessment of Molecular Aspects of Pathoetiology in Multiple Sclerosis.

Authors:  Petra Hnilicová; Oliver Štrbák; Martin Kolisek; Egon Kurča; Kamil Zeleňák; Štefan Sivák; Ema Kantorová
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.